This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



mexiletine (Namuscla®)


Reference No. 2309

Publication date:
01/04/2019


Appraisal information

mexiletine (Namuscla®) 167 mg hard capsule


Company: Lupin (Europe) Limited
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/03/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, mexiletine (Namuscla®) cannot be endorsed for use within NHS Wales for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders
Statement of Advice (SOA)
Download